Jade Biosciences (JBIO) Non-Current Assets (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Non-Current Assets came in at $916000.0 in Q1 2026, up 472.5% YoY from $160000.0 in Q1 2025, and down 5.08% on a QoQ basis from $965000.0 in Q4 2025.
Jade Biosciences (JBIO) Non-Current Assets (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Non-Current Assets data on file, last reported at $916000.0 in Q1 2026.
- Quarterly Non-Current Assets rose 472.5% year-over-year to $916000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 13.89% YoY) and the FY2025 annual result came in at $965000.0, down 69.32% from the prior year.
- Non-Current Assets fell to $916000.0 in Q1 2026, from $965000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $3.8 million in Q1 2023 to a low of $160000.0 in Q1 2025.
- A 5-year average of $2.1 million and a median of $2.2 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets plunged 95.53% — and 2026, when it jumped 472.5%.
- Tracing JBIO's Non-Current Assets over 5 years: stood at $3.8 million in 2022, then retreated by 16.27% to $3.2 million in 2023, then declined by 1.29% to $3.1 million in 2024, then slumped by 69.32% to $965000.0 in 2025, then retreated by 5.08% to $916000.0 in 2026.
- The last three Non-Current Assets figures came in at $916000.0 (Q1 2026), $965000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | 862,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 862,000.00 |
| Mar 31, 2026 | 916,000.00 |
| Dec 31, 2025 | 965,000.00 |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 984,000.00 |
| Mar 31, 2025 | 160,000.00 |
| Dec 31, 2024 | 3.15 Mn |
| Sep 30, 2024 | 354,000.00 |
| Jun 30, 2024 | 934,000.00 |
| Mar 31, 2024 | 3.58 Mn |
| Dec 31, 2023 | 3.19 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 3.29 Mn |
| Mar 31, 2023 | 3.82 Mn |
| Dec 31, 2022 | 3.81 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.24 Mn |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 1.03 Mn |
| Sep 30, 2021 | 1.02 Mn |